Protox doses first patient in Phase 2 BPH clinical trial

19-May-2008

Protox Therapeutics Inc. announced the enrolment and successful dosing of the first patient in a Phase 2 clinical trial evaluating PRX302 to treat benign prostatic hyperplasia (BPH), or enlarged prostate.

"This milestone sets the stage for a very exciting time for Protox this year as we embark upon dosing patients in as many as three Phase 2 clinical trials," said Dr. Fahar Merchant, President and Chief Executive Officer of Protox. "We are very pleased with the rapid advances we have made on this important project and look forward to completing patient enrolment and releasing results before the end of this year. We believe that PRX302 has the potential of establishing a new standard of care for a disease that affects millions of men worldwide."

Oral medications used to treat BPH can cause side effects such as sexual dysfunction and dizziness and become ineffective over time. Surgical procedures to treat males with BPH are often associated with complications and lengthy recovery times. Results from a recently completed Phase 1 BPH study indicate that PRX302 is safe and well tolerated and shows very encouraging signs of therapeutic activity. The goal of this Phase 2 study will be to optimize dosing in order to fully exploit the therapeutic potential of PRX302, while maintaining its excellent safety profile.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance